ULI-EAP-100 Expanded access to ulixertinib (bvd-523) in patients with advanced mapk pathway-altered malignancies
- Trial Category: Other Solid Tumor
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Cancer Partners of Nebraska, Lincoln, NE location
About
This study requires that the tumor is MAPK pathway altered. The Oncology team will determine this
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields